NCT03512340: Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic or untreated brain metastases (including leptomeningeal metastases); Patients previously treated with an anti-CD47 antibody or SIRP-alpha targeted therapy

Comments are closed.

Up ↑